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Abstract
Purpose Large cohort studies are needed taking into account
cancer-related, personal, biological, psychobehavioral, and
lifestyle-related factors, to guide future research to improve
treatment and supportive care. We aimed to evaluate the
feasibility of a comprehensive baseline assessment of a cohort
study evaluating the course of quality of life (QoL).
Methods Newly diagnosed head and neck cancer (HNC) pa-
tients were asked to participate. Assessments consisted of
questionnaires (635 items), a home visit (including a psychi-
atric interview, physical tests, and blood and saliva collection),
and tissue collection. Representativeness of the study sample
was evaluated by comparing demographics, clinical factors,
depression, anxiety, and QoL between responders and non-
responders. Feasibility was evaluated covering the number of
questions, time investment, intimacy, and physical burden.
Results During the inclusion period (4 months), 15 out of 26
(60 %) patients agreed to participate. Less women participated,
13% in responders group versus 63% in non-responders group
(p=0.008). No other differences were found between re-
sponders and non-responders. Responders completed more
than 95 % of the questionnaires’ items and rated the number
of questions, time investment and intimacy as feasible, and the
physical and psychological burden as low. It took on average
3 h to complete the questionnaires and 1.5 h for the home visit.
Conclusions This study reveals that a comprehensive assess-
ment including various questionnaires, physical measure-
ments, and biological assessments is feasible according to
patients with newly diagnosed HNC. A large prospective
cohort study has started aiming to include 739 HNC patients
and their informal caregivers in the Netherlands.
Keywords Head and neck neoplasm . Health-related quality
of life . Physical examination . Pilot study . Feasibility
Introduction
Worldwide, each year, head and neck cancer (HNC) accounts
for more than 633,000 new cases and over 355,000 deaths [1].
In the Netherlands, the incidence of HNC increased from
2 ,474 in 2001 to 2 ,970 in 2011 [h t tp : / /www.
cijfersoverkanker.nl/. 2013. Ref Type: Online Source],
mainly due to aging, increased tobacco consumption by
females in the 1980s, and an increasing number of human
papilloma virus-related oropharyngeal carcinomas [http://
data.euro.who.int/hfadb. 2014. Ref Type: Online Source, 2,
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3]. Current 5-year survival rate of patients with advanced
HNC in the Netherlands is approximately 60 % [http://www.
cijfersoverkanker.nl/. 2013. Ref Type: Online Source]. For
certain subsites, e.g., oropharyngeal carcinoma, survival is
improving [4]. Due to the increasing incidence and
improved survival rates, more patients with HNC have to
cope with various physical and psychosocial problems
associated with the cancer diagnosis and treatment, such as
decreased general and mental health, oral dysfunction,
swallowing and speech problems, and emotional distress,
severely compromising health-related quality of life
(HRQoL) [5–12]. Compared to other types of cancer, includ-
ing breast, colon, and prostate cancers, HNC patients report
high levels of distress [13]. At the same time, an increasing
number of studies suggest that HRQoL has prognostic value
for survival [14–20]. However, most previous studies on
HRQoL and survival in HNC patients had some limitations
related to relatively small sample sizes, the focus on specific
subsites of HNC, adjustment for only a few confounders (e.g.,
lifestyle, demographic, and clinical characteristics), or inclu-
sion of only a few aspects of HRQoL (16–25). Furthermore,
little is known about the course of HRQoL of patients with
HNC and its determinants across the cancer trajectory. Previ-
ous studies showed that several domains of HRQoL, including
general health, mental health, physical function, appearance,
employment, and social functioning declined during and im-
mediately after treatment and improved after 6 months [5, 6,
10–12, 21–24]. Studies including long-term follow-up showed
that HRQoL stabilized 1 year after treatment and was not
significantly different from baseline levels at 5-year follow-up
[5–7, 23, 24]. However, Mehanna et al. [12] reported 10 years
after diagnosis, significantly lower HRQoL scores than before
treatment, which was recently confirmed by Oskam et al. [25].
A recent review among patients with HNC [26] showed
that the majority of studies examining the course of HRQoL
over time were limited by their retrospective study design,
their focus on only a few aspects of HRQoL instead of all
domains [27], the use of patient-reported outcomes (PROs)
only, the small sample size, and lack of pre-treatment mea-
surements of HRQoL [28]. In addition, studies examining the
association between HRQoL and survival lacked to adjust for
all relevant confounders and different study designs were used
[29]. Therefore, there is need for a large multi-institutional
prospective cohort study evaluating the course of HRQoL in
patients with HNC and its relation with survival integrating all
relevant cancer-related, personal, genetic, biological,
psychobehavioral, physical, lifestyle-related, and social fac-
tors. Comprehensive insight in all these factors assessed in a
standardized manner is necessary to unravel these complex
associations. A study of this magnitude has never been carried
out among patients with HNC, and it is unclear whether it is
feasible to conduct such an extensive objective assessment of
physical and cognitive function, lifestyle, a psychiatric
interview, and collection of blood, saliva, and tumor tissue,
in addition to a large number of PROs. Thus, the aim of the
present study is to assess the feasibility of a comprehensive
baseline assessment among patients with HNC.
Materials and methods
Sample and setting
As part of clinical routine in our institution, all newly diag-
nosed HNC patients are asked to fill out questionnaires on
HRQoL and emotional distress during their first visit via
OncoQuest [30]. OncoQuest is a touch screen computer sys-
tem to monitor HRQoL in clinical practice and includes three
questionnaires: the European Organization for Research and
Treatment of Cancer (EORTC), Quality of Life Questionnaire
core module (QLQ-C30), [31, 32], EORTC Head and Neck
Module (HN35) [33], and Hospital Anxiety and Depression
Scale (HADS) [34].
The 30-itemEORTCQLQ-C30 includes a global quality of
life scale, five function scales regarding physical, role, emo-
tional, cognitive, and social functioning, three symptom scales
(nausea and vomiting, fatigue, and pain), and six single items
related to dyspnea, insomnia, loss of appetite, constipation,
diarrhea, and financial difficulties [31, 35]. The 35-item
EORTC QLQ-HN35 is a tumor-specific module addressing
symptoms specifically associated with HNC, including pain,
swallowing, senses, speech, social eating, social contact, and
sexuality, as well as ten single items covering problems with
teeth, dry mouth, sticky saliva, cough, opening the mouth
wide, weight loss, weight gain, use of nutritional supplements,
feeding tubes, and painkillers [32]. The HADS is a 14-item
scale for measuring emotional distress and includes a total
scale and an anxiety (HADS-A) and depression (HADS-D)
subscale [34]. A total score of >15 is used as an indicator of a
high psychological distress. For the subscales, cutoff points of
≥8 are indicators of high levels of anxiety or depression.
From January to mid-April 2012, every new patient with
HNC was screened for eligibility for the current feasibility
study. Patients presenting with oral, oropharyngeal,
hypopharyngeal, and laryngeal cancers and patients with neck
metastasis of unknown primary tumor with proven squamous
cell histology (aged 18 years or older, treated with curative
intent), who were able to write, read, and speak Dutch were
eligible. Patients suffering from severe psychiatric comorbid-
ities (e.g., schizophrenia, Korsakov’s syndrome, and severe
dementia) were excluded. Eligible patients were asked to
participate in this feasibility study by the treating surgeon,
and subsequently, the research physician provided more de-
tailed information about the study and handed out written
information. Non-participants were asked for their reason for
not participating. All patients signed an informed consent
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statement prior to participation. The Institutional Review
Board of the VU University Medical Center approved the
study.
Procedures and assessments
After all eligible patients filled out the three questionnaires
(EORTC QLQ C30, EORTC HN35, HADS) as clinical pro-
cedure, study participants filled out the comprehensive base-
line assessment, consisting of 36 questionnaires and in total
762 items, which took place before the start of treatment. The
questionnaires consisted variable subdomains, including gen-
eral and disease-specific QoL, cancer-related, personal,
psychobehavioral, physical, lifestyle-related, social factors,
and health care costs (Table 1). According to patient’s prefer-
ence, the PROs were sent by postal mail, or a link was e-
mailed to fill out the PROs via internet. Subsequently, the
research physician visited the patients at their homes or in the
hospital according to preference of the patients, to conduct a
psychiatric interview, physical tests, and collection of blood.
At the end of the visit, patients were instructed to collect five
saliva samples during the same evening and next morning and
to wear an accelerometer (Actitrainer, Actigraph, Fort Walton
Beach, Florida) for the next 7 days. Three to 5 days after the
home visit, a telephone interview was conducted to assess diet
using a 24-h recall. Tumor tissue was gathered during the
participants’ panendoscopic procedure, which is performed
as a part of the diagnostic workup. This procedure aims to
determine the field of surgery and to investigate the presence
of other tumors. During this panendoscopy, a supplemental
biopsy was taken for the current study besides the diagnostic
tissue collection for the pathology department. An overview
of all outcome measures included in the baseline assessment
protocol is presented in Table 1. The assessment protocol was
developed in collaboration with the coordinator of the Neth-
erlands Study of Depression and Anxiety (NESDA) study
[33]. NESDA is a large prospective cohort study which aims
to describe the long-term course and consequences of depres-
sive and anxiety disorders.
Outcome measures
The primary outcome of this study was the feasibility of the
baseline assessment protocol, as evaluated by representative-
ness of the study population, achievability of baseline assess-
ments, and accuracy of the protocol.
Representativeness was assessed by the following questions:
– What percentage of eligible patients is willing to
participate?
– What are the main reasons for not participating?
– Are there differences between participants and non-
participants regarding age, gender, diagnosis, comorbid-
ity, stage, treatment, HRQoL, and emotional distress?
Achievability was evaluated by the following items:
– A study-specific questionnaire consisting of four-point
Likert scales (not feasible, a bit feasible, quit feasible,
very much feasible) covering the number of items, time
investment, intimacy and burden of the PROs, and the
home visit.
– The number of items successfully completed was regis-
tered as well as the time needed to complete the PROs, as
estimated by patients and the home visits as measured by
a research physician.
Accuracy of the assessment protocol was evaluated using the
following questions:
– Is the protocol clear to other assessors (i.e., two experi-
enced fieldworkers and a coordinator from the NESDA
study)?
– Is the assessment protocol complete, clear, and accurate
according to the research physician (A.N.)?
Statistical analysis
Statistical analyses were performed using Statistical Package
for the Social Sciences (SPSS) 20.0 (SPSS Inc., Chicago, IL).
Descriptive statistics (mean/standard deviation (SD)/propor-
tions) were generated for demographic and clinical character-
istics, emotional distress, and HRQoL and questions on rep-
resentativeness and achievability.
Differences in age, gender, diagnosis, comorbidity, stage,
treatment, emotional distress, and HRQoL between partici-
pants and non-participants were tested with Mann-WhitneyU
test or χ2 test. For the comparison of emotional distress and
HRQoL, we used results from the OncoQuest database.
Results
Representativeness
During a time period of 14 weeks, 26 eligible patients were
asked, of whom 15 (58 %) were willing to participate (Fig. 1).
The main reason for not participating was the high burden of
recently being diagnosed with cancer, leaving no room for
additional inconvenience (n=8; 30 %). However, all of these
patients indicated that they would have been interested in
participation at another point in time. Other reasons for non-
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Table 1 Overview of all outcome measures included in the assessment protocol: patient-reported outcome, (home) visit (physical tests and interviews),
and biological and clinical factors




Generic EuroQuol-5D (EQ-5D) 6
Disease-specific European Organisation for Research and Treatment of Cancer Quality of Life
Questionnaire-core 30 (EORTC QLQ-C30)
30
Tumor-specific European Organisation for Research and Treatment of Cancer Quality of Life
Questionnaire module, Head and Neck 35 (EORTC QLQ-HN35)
35
Speech Speech Handicap Index (SHI) 31
Swallowing Swallowing QoL Questionnaire (SwalQoL) 47
Shoulder Shoulder Disability Questionnaire (SDQ) 16
Hearing Caron questionnaire on hearing 19
Malnutrition Short Nutritional Assessment Questionnaire (SNAQ) 4
Cancer-related factors
Comorbidity Adult comorbidity evaluation (ACE-27) 2
Personal factors
Personality Neuroticism-Extroversion-Openness-Five factor inventory (NEO-FFI) 60
Locus of control Pearlin and Schooler mastery scale (PSMS) 5
Coping Mental Adjustment to Cancer scale (MAC) 39
Self-efficacy Generalized self-efficacy scale (GES) 10
Well-being Posttraumatic Growth Inventory (PTGI) 21
Physical appearance Body Image Scale (BIS) 10
Life events Brugha Questionnaire 13
Coping Utrechtse Coping List (UCL) 46
Psychobehavioral factors
Severity anxiety/depression Hospital Anxiety and Depression Scale (HADS) 14
Fatigue Multidimensional Fatigue Inventory (MFI) 20
Fatigue Fatigue Quality List (FQL) 1
Sleep quality Pittsburgh Sleep Quality Index (PSQI) 15
Fear of recurrence Cancer Worry Scale (CWS) 8
Cognition Cognitive Failure Questionnaire (CFQ) 25
Physical factors
Sexual function
Males International index of Erectile Function (IIEF) 19
Females Female Sexual Function Index (FSFI) 15
Females Study-specific questionnaire on fertility 16
Lifestyle-related factors
Alcohol intake Study-specific questions 13
Alcohol dependence Study-specific questions 7
Drug use Study-specific questions 7
Smoking Study-specific questions 8
Nicotine dependence Study-specific questions 5
Physical activity Physical Activity Scale for the Elderly (PASE) 31
Leisure Study-specific questions 15
Social factors
Social support Social Support List Interactions (SSL-I12) 12
Participation Impact on Participation and Autonomy (IPA) 43
Health care use/costs
Need and use care Study-specific questionnaire 28
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participation were not willing to participate in any research
project (n=2; 8 %) or not willing to participate in this specific
study protocol (n=1; 4 %).
Except for gender, no differences in demographic and
clinical characteristics, emotional distress, and HRQoL were
found between participants and non-participants. The propor-
tion of women among non-participants (64 %) was higher
than among participants (13 %), p=0.008 (Table 2).
One participant (7 %) and two non-participants (18 %) did
not fill out OncoQuest, and consequently, their data on
HRQoL and psychological distress were missing.
Achievability
All participating patients filled out the questionnaires with 95–
99 % (n=8) to 100 % (n=7) of the items completed. Two
Table 1 (continued)
Outcomes Measurement instrument Number of
items
Costs Trimbos and iMTA questionnaire on Costs associated with Psychiatric




Demographic Standard questions 23
Socioeconomic status/literacy Standard questions 27
Psychobehavioral factors
Presence MDD Composite international diagnostic interview (CIDI)—Major Depressive Disorder (MDD) Variable
Anxiety disorder Composite international diagnostic interview (CIDI)—Anxiety disorders (GAD, SOC, PAN, AG) Variable
Pain Brief Pain Inventory (BPI) 13
Physical factors
Speech quality Speech recording (perceptual and objective analyses) n.a.
Pulmonary function Peak flow n.a.
Strength—upper extremity JAMAR handgrip dynamometer n.a.
Strength—lower extremity 30s chair stand test n.a.
Cardiorespiratory fitness Chester Step test n.a.
Body composition Height, weight, body mass index, waist+hip circumference, thickness of four skin folds n.a.
Blood pressure Systolic and diastolic blood pressure n.a.
Visual motor processing speed Trail making test part A n.a.
Executive functioning Trail making test part B n.a.
Activity monitoring Accelerometer n.a.
Food 24-h recall n.a.
Social factors
Loneliness De Jong-Gierveld Loneliness Scale 11
Health care use/costs
Work productivity Productivity and disease questionnaire (PRODISQ) 14
Biological and clinical factors
Cancer-related factors
Cancer location/stage Standard questions, from medical record n.a.
Treatment modality Standard questions, from medical record n.a.
Biological factors
Tumor markers Tumor tissue n.a.
Biomarkers Blood n.a.
General laboratory Blood n.a.
DNA Blood n.a.
Proteomics Blood n.a.
Gene expression (RNA) Blood n.a.
MDD major depressive disorder, n.a. not applicable, AD generalized anxiety disorder, SOC social phobia, PAN panic disorder, AG agoraphobia
Support Care Cancer (2014) 22:3321–3330 3325
patients did not fill out the questionnaire on sexuality because
they were not sexually active. No problems were detected
with other questionnaires. The majority of the patients
(80 %) preferred the pen-and-paper version over the
internet-based method. Completing the PROs took on average
167 min (range 100–270). All patients filled out the PROs
within 1 week. One patient needed 270 min to complete the
PROs due to concentration problems. Compared to the other
patients, this was exceptionally long (range without this par-
ticular patient 100–210 min).
Most patients (n=12) preferred the research physician to
conduct the interview, physical tests, and blood collection
during a home visit. Assessments of the other three patients
were conducted during a hospital visit. The visits took on
average 100 min (range 60–145).
Some of the physical tests and biological sample collec-
tions could not be performed (Table 3). The Chester step test
was not conducted in three patients due to physical impair-
ments such as an amputated leg, cardiac history, or severe
mobility problems. Accelerometer data of six patients were
missing due to the following: surgery within a few days after
the baseline measurement (n=1), a percutaneous endoscopic
gastrostomy (PEG) tube placement within a few days after
baseline assessment (n=2), wheelchair dependence (n=1),
crutches dependence in daily life (n=1), and losing the accel-
erometer (n=1). All other physical tests were completed by all
patients. The cognitive test and the psychiatric interview were
conducted in all patients without experiencing any problems.
Dietary telephonic interview at the end of the assessments
were taken in 11 (73 %) patients. Four interviews were missed
because treatment already started. Blood and saliva samples
were collected in 13 patients (87 %) patients; two patients
refused to give blood samples, and two patients did not return
their saliva samples. Tumor tissue from eight participants
(53 %) was collected during panendoscopy at the VU Univer-
sity Medical Center. Reasons for not collecting supplemental
biopsies were as follows: unknown primary tumor (n=2), no
extra biopsies during panendoscopy because of immediate
surgery (n=3), biopsy already taken in outpatient clinic (n=
1), and unknown (n=1).
Patients evaluated the number of items, the time investment
and personal or intimate character of the PROs, and the
physical tests as feasible to very much feasible (Table 4).
Regarding intimacy of questions, one patient found a ques-
tionnaire on sexuality too intimate and therefore rated the item
intimacy as “a bit feasible” for intimacy. One patient found the
time investment of the home visit too long. Due to the pres-
ence of a child, this home visit took much longer compared to
the other patients (145 min).
Protocols
Generally, the research physician reported the home visits to
be very pleasant. Concentration problems were present in two
patients according to the research physician. Another patient
was somewhat long-winded and expanding to various topics
during the (psychiatric) interview and had to be redirected to
the questions continuously. No adverse events occurred dur-
ing the visits. Furthermore, the protocols were independently
judged as clear by the research physician, two other experi-
enced fieldworkers, and a research coordinator.
Discussion
This pilot study showed that it is feasible to conduct a compre-
hensive baseline assessment compromising a large number of
PROs, interviews, physical tests, and biological sample
Fig. 1 Flowchart of all eligible
patients and the reasons for
non-participation
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collection among newly diagnosed HNC patients. We found the
study sample to be a representative reflection of patients with
HNC, and the achievability of the assessment protocol was high.
Representativeness
The present study showed that 58% of newly diagnosed HNC
patients were willing to participate in a comprehensive
assessment. Our response rate was somewhat lower compared
to 76–97% reported in the other prospective cohort studies on
HRQoL in HNC patients [5, 7, 10, 36, 37]. Differences in
response rate may be related to the large number of question-
naires included, since only one to three questionnaires were
included in the previously mentioned studies. Taking into
account our comprehensive assessments, we consider our
response rate to be acceptable. Of all eligible patients, 30 %
Table 2 Differences in demographic and clinical characteristics, psychological distress, and health-related quality of life between participants and non-
participants
Characteristics Participants (n=15) Non-participants (n=11) Difference (p value)
Gender, n (%) male 13 (87) 4 (36) 0.008
Age, mean±SD (range) (years) 63±12 (40–80) 62±8 (52–78) 0.926
Tumor location, n (%) 0.986
Oral cavity 4 (27) 3 (27) –
Oropharynx 5 (33) 3 (27) –
Hypopharynx 0 (0) 0 (0) –
Larynx 5 (33) 4 (36) –
Unknown primary 1 (7) 1 (9) –
Disease stage, n (%) 0.749
I 2 (13) 2 (18) –
II 1 (7) 1 (9) –
III 5 (33) 3 (27) –
IV 7 (46) 5 (45) –
Type of treatment, n (%) 0.486
CHRT 8 (53) 4 (36) –
RT 4 (27) 2 (18) –
SURG 1 (7) 3 (27) –
TOE+SN 2 (13) 2 (18) –
Comorbidity, n (%)
None 4 (27) 3 (27) 0.683
Mild 3 (20) 3 (27) –
Moderate 7 (47) 3 (27) –
Severe 1 (7) 2 (18) –
Participant (n=14) Non-participant (n=9)
HADS
Total score, mean±SD 10±8 11±5 0.587
Depression score ≥8, n (%) 3 (21 %) 1 (11 %) 0.546
Anxiety score ≥8, n (%) 3 (21 %) 4 (44 %) 0.262
Total score >15, n (%) 3 (21 %) 2 (22 %) 0.966
EORTC QLQ-C30, mean±SD
Global quality of life 78±15 64±29 0.145
Physical function 87±15 81±23 0.480
Role function 88±24 74±30 0.229
Emotional function 60±22 69±20 0.296
Cognitive function 88±21 94±8 0.402
Social function 92±18 85±28 0.508
SD standard deviation, CHRT chemoradiation therapy, EORTC QLQ C30 European Organization for Research and Treatment of Cancer Quality of Life
Questionnaire Core 30, HADS Hospital Anxiety and Depression Scale, RT radiotherapy, SURG surgery, TOE+SN transoral excision and sentinel node
procedure
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would like to participate in the study but not at this specific
moment. The most important argument for not participating
was that the protocol seems too burdensome. For a future
study, we can now better inform eligible patients on the time
investments and feasibility of the protocol. The remaining
12 % of eligible patients were not willing to participate in
any study, and it is likely that this proportion will also be
missed in a forthcoming cohort study.
In our study, females were found to be less likely to
participate, which is in contrast to the pilot study of
Hammerlid et al. [38] who found all non-participants to be
men. Another prospective study on long-term HRQoL in
patients with HNC found no significant differences between
participants and non-participants in demographic and clinical
characteristics [7]. Therefore, our under-representativeness of
women may be coincidental. On the other hand, it may be
related to the higher, but non-significant anxiety levels we
found among non-participants, since, in patients with HNC,
women are more likely to report higher levels of anxiety than
men [39]. However, due to the small sample size, the non-
significant differences in anxiety between participants and
non-participants should be interpreted with caution. Studies
among newly diagnosed cancer patients are at risk for selec-
tion bias underestimating problems related to emotional dis-
tress and HRQoL. Therefore, we will closely monitor differ-
ences in main characteristics between responders and non-
responders in a future cohort study.
Achievability
Despite the considerable time investment (average of
270 min in total), our results showed that almost all patients
found the study to be feasible to very much feasible. How-
ever, some patients experienced some problems with the
questionnaires on sexuality, particularly those who were
not sexually active. To avoid unnecessary confrontation with
intimate questions in a future cohort study, we will therefore
add a remark at the start of this questionnaire that patients
can skip this questionnaire if not applicable. Regarding the
(home) visits, we noticed that a quiet environment is impor-
tant to prevent unnecessary delay in conducting the interviews
and physical tests.
The home visits were almost fully completed. Blood and
saliva was collected in 87 % of the patients which we consid-
ered to be acceptable. A relatively large proportion (40 %) of
patients did not wear the accelerometer due to various reasons,
of which some were largely unavoidable such as amputated
leg and crutches dependence, whereas others may be
prevented or (rapidly) solved. In this study, we did not give
an accelerometer to patients undergoing a PEG tube place-
ment which potentially hampers physical activities for a cer-
tain period of time. However, it seems that the patients may be





Reasons for not performing
physical assessments
Grip strength 100 –
30-s chair stand test 93 Amputated leg (n=1)
Step test 80 Amputated leg (n=1)
Cardiac history (n=1)
Severe immobility (n=1)
Accelerometer 53 Amputated leg (n=1)
Severe immobility (n=1)
PEG tube placement (n=2)
Lost accelerometer (n=2)






Reasons for not performing
biological assessment
Blood collection 87 Unwillingness (n=2)
Saliva collection 87 Not returned (n=2)
Tissue collection 53 Biopsy already taken (n=1)
No extra biopsies, direct
surgery (n=3)
No extra biopsies, unknown
primary tumor (n=2)
Reason not registered (n=1)
PEG percutaneous endoscopic gastrostomy
Table 4 Feasibility of the questionnaires and home visit
Not feasible A bit feasible Feasible Very much feasible
Questionnaires, n (%)
Number of items – – 12 (86) 2 (14)
Time investment – – 6 (40) 8 (57)
Personal or intimate character of questions – 1 (7) 7 (50) 6 (43)
Home visits, n (%)
Number of questions – – 3 (21) 11 (79)
Time investment 1 (7) – 4 (29) 9 (64)
Personal or intimate character of questions – – 2 (14) 12 (86)
Burden of physical assessments – – 2 (14) 12 (86)
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able to wear an accelerometer. Furthermore, a new device may
quickly be sent to patients who lost their device. Tissue
collection was successful in 53 % of the participants. In most
cases, supplemental tumor biopsies for this study were not
taken due to logistical reasons including immediate surgical
treatment of tumor, biopsies already taken in outpatient clinic,
or because of an unknown primary tumor. In this pilot study,
we did not collect tumor tissue samples from the surgical
specimen from the pathology department, but we are planning
to do so in a future study if tumor tissue is available.
Strengths and limitations
To our knowledge, this pilot study is the first to evaluate a
comprehensive assessment protocol of this extent in newly
diagnosed HNC patients before treatment. In addition, the
inclusion of objective physical tests and biological sample
collection in addition to PROs is a strength of this study.
Another strength of this study was the ability to compare data
on HRQoL and psychological distress between participants
and non-participants, providing a thorough investigation of
the representativeness of the included study sample. This
study was limited by its focus on baseline assessment only,
and we did not collect data on the feasibility of follow-up
measurements. However, other longitudinal studies on HRQoL
in patients with HNC reported acceptable dropout rates varying
between 6 and 14 % [7, 36]. Whether dropout rates will be
similar in the forthcoming cohort study remains unclear. Fur-
thermore, while almost all single questionnaires were validated,
it is unclear whether assessment of multiple single valid ques-
tionnaires impacts the validity. A previous study examining the
influence of the structure of questionnaires on response out-
comes showed that changes in order of questionnaires did not
substantially affect the outcomes [40]. In the present study,
assessments were conducted in a hierarchical order, starting
with the main outcome measure health-related quality of life,
following by questionnaires assessing covariates.
In conclusion, this study showed that it is feasible to
conduct a comprehensive assessment protocol including
PROs, interviews, physical tests, and collection of biological
samples in newly diagnosed HNC patients before the start of
treatment. Therefore, we will set up a large multicenter cohort
study in patients with HNC evaluating the course of HRQoL
over time starting at diagnosis and the relationship between
HRQoL and survival, taking into account cancer-related, per-
sonal, genetic, biological, psychobehavioral, physical, life-
style-related, and social factors, the Netherlands Quality of
life and Biomedical Cohort studies in cancer, Head and Neck
(NET-QUBIC_HNC).
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